- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 21
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 21, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 21.
Number 5: Stakeholder groups, including the American College of Rheumatology and the Biotechnology Innovation Organization are praising the enactment of the FDA Reauthorization Act of 2017, calling the law critical to bringing biosimilar products to the marketplace.
Number 4: Drug maker Alexion has announced 3 new US patents that will defend its Soliris against biosimilar competition. Alexion also announced that the European Commission has granted the drug an extended indication for myasthenia gravis.
Number 3: A recently published study shows that biosimilar filgrastim is safe, effective, and well tolerated in both primary and secondary prevention of chemotherapy-induced febrile neutropenia.
Number 2: The FDA has signed an agreement to share confidential information, including trade secrets and inspection reports, with European regulators.
And Number 1: The Center for Biosimilars® Peer Exchange®, titled “Clinical Advances and Challenges with Biosimilars,” kicks off with an expert discussion of the adoption of biosimilar treatments in the United States and Europe.
Finally, last week, our newsletter asked you to share your thoughts about how the FDA should address the deficiencies it observed at Biocon’s manufacturing facility. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
